Chronic Obstructive Pulmonary Disease Clinical Trial
— PT009001Official title:
A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD
Verified date | May 2018 |
Source | Pearl Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD. The overall objective is to demonstrate that the combination of budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009) provides benefit on lung function compared with BD MDI in subjects with moderate to severe COPD.
Status | Completed |
Enrollment | 180 |
Est. completion date | March 1, 2015 |
Est. primary completion date | March 1, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Informed Consent Form (ICF) prior to any study related procedures - COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) - Tobacco Use: Current or former smokers with a history of at least 10 pack years of cigarette smoking - Women of non-childbearing potential or medically acceptable contraception for women of child-bearing potential and males with female partners of childbearing potential - Severity of Disease: Subjects with an established clinical history of COPD and severity defined as: FEV1/forced vital capacity (FVC) ratio of <0.70; At Screening (Visit 1a/b), post bronchodilator FEV1 must be <80% predicted normal value, calculated using NHANES III (Third National Health and Nutrition Examination Survey) reference equations; the measured FEV1 must also be =30% of predicted normal value; at Visit 2, the average of the 60 minutes and 30 minutes pre dose FEV1 assessments must be <80% predicted normal value calculated using NHANES III reference equations - Screening clinical laboratory tests must be acceptable to the Investigator - Screening ECG must be acceptable to the Investigator - Chest x ray or computerized tomography (CT) scan within 6 months prior to Visit 1a must be acceptable to the Investigator. Exclusion Criteria: - Significant diseases other than COPD, ie., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study - Pregnancy, nursing female subjects, or subjects trying to conceive, or not using medically acceptable form of contraception - Asthma: Subjects who have a primary diagnosis of asthma (Note: Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis). - Alpha 1 Antitrypsin Deficiency: Subjects who have alpha 1 antitrypsin deficiency as the cause of COPD -Active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea (ie., in the opinion of the Investigator severity of the disorder would impact the conduct of the study)- - Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study - Poorly Controlled COPD - History of ECG abnormalities - Cancer not in complete remission for at least 5 years - Clinically significant, symptomatic prostatic hypertrophy - Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening - Clinically significant bladder neck obstruction or urinary retention - Inadequately treated glaucoma - History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study |
Country | Name | City | State |
---|---|---|---|
United States | Pearl Investigative Site | Charlotte | North Carolina |
United States | Pearl Investigative Site | Cincinnati | Ohio |
United States | Pearl Investigative Site | Clearwater | Florida |
United States | Pearl Investigative Site | Columbus | Ohio |
United States | Pearl Investigative Site | Dublin | Ohio |
United States | Pearl Investigative Site | Easley | South Carolina |
United States | Pearl Investigative Site | Edina | Minnesota |
United States | Pearl Investigative Site | Greenville | South Carolina |
United States | Pearl Investigative Site | Medford | Oregon |
United States | Pearl Investigative Site | Minneapolis | Minnesota |
United States | Pearl Investigative Site | Panama City | Florida |
United States | Pearl Investigative Site | Rolling Hills Estates | California |
United States | Pearl Investigative Site | Saint Charles | Missouri |
United States | Pearl Investigative Site | Spartanburg | South Carolina |
United States | Pearl Investigative Site | Tampa | Florida |
United States | Pearl Investigative Site | Winter Park | Florida |
United States | Pearl Investigative Site | Woodbury | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Pearl Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FEV1 AUC0-12 on Day 29 | Change from Baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12) | Day 29 | |
Secondary | Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days | Over 28 days | ||
Secondary | Peak Change From Baseline in FEV1 (in Liters) Day 15 | Day 15 | ||
Secondary | Peak Change From Baseline in FEV1 (in Liters) Day 29 | Day 29 | ||
Secondary | Peak Change From Baseline in FEV1 on Day 1 | Day 1 | ||
Secondary | Forced Vital Capacity (FVC) AUC0-12 on Day 29 | Day 29 | ||
Secondary | Transition Dyspnea Index (TDI) Focal Score on Day 29 | Min/Max Range of TDI scale -9 (major deterioration) to +9 (major improvement) | Day 29 | |
Secondary | Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment | Visit 12-13 (7 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|